VivoSeq
Neurology

Vestibular Schwannoma

15

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Vestibular schwannoma is an emerging landscape with 15 programs across 5 companies. The most active players are GSK, Prism Pharmaceuticals, Bayer. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

10/100

Completion Rate

69/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

GSK logo

GSK

1 program

Phase 1P

Prism Pharmaceuticals

2 programs

Phase 2Bayer logo

Bayer

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2A

Azurity Pharmaceuticals

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

12 of 15 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody17%Protein / enzyme17%Radiopharmaceutical17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed9 · 53%
Terminated3 · 18%
Active, not recruiting2 · 12%
Suspended1 · 6%
Unknown status1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT01199978·30 enrolled
Study of Aspirin in Patients With Vestibular Schwannoma
Active, not recruiting·MMassachusetts Eye and Ear Infirmary·Phase 2·NCT03079999·97 enrolled
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
Not yet recruiting·—·Phase 3·NCT07116811·364 enrolled
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00863122·26 enrolled
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Completed·MMayo Clinic·Phase 2·NCT04351373·12 enrolled
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
Completed·National Cancer Institute (NCI)·Phase 2·NCT01207687·14 enrolled
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT04283669·12 enrolled
Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma
Completed·—·N/A·NCT02963896·20 enrolled
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT01767792·22 enrolled
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Completed·NNYU Langone Health·Phase 2·NCT02129647·13 enrolled
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01490476·10 enrolled
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Completed·NNYU Langone Health·Phase 1·NCT01880749·5 enrolled
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
Suspended·NNorthwell Health·Phase 1·NCT01083966·30 enrolled
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Terminated·JJonsson Comprehensive Cancer Center·Phase 2·NCT01345136·4 enrolled
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Terminated·MMassachusetts Eye and Ear Infirmary·Phase 1·NCT02282917·7 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)